- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02371265
Early ART Initiation Among HIV-positive Pregnant Women in Central Mozambique
Study Overview
Detailed Description
For over 10 years, services to prevent maternal to child HIV-1 transmission (PMTCT) have been scaled-up and integrated into antenatal care (ANC) in the national health system across Mozambique. In 2004, scale-up of anti-retroviral treatment (ART) also began in Mozambique and is now provided at hundreds of health units. In 2010, the World Health Organization developed new treatment guidelines, termed "Option B" that emphasized early initiation of ART in antenatal care for all HIV-positive pregnant women. In 2012, the WHO issued a programmatic update endorsing a third option termed "Option B+" in which HIV positive pregnant women initiate ART during pregnancy regardless of disease progression and continue treatment for life.
The new "Option B+" approach has been adopted by the Ministry of Health (MoH) in Mozambique and is in the early phases of implementation. As in many African settings, numerous health system factors present major challenges to successful adoption of the guidelines. In Mozambique, ANC and HIV testing coverage is high but there is substantial loss-to-follow-up (LTFU) at successive stages in the treatment cascade, limited counseling for women and many barriers to actively tracking those women lost to follow-up. Early Ministry of Health data suggests significant challenges remain for long-term adherence for women started on ART via the new Option B+ framework in Manica and Sofala provinces and throughout Mozambique.
The successful implementation of new WHO guidelines therefore requires major streamlining of links among ANC, PMTCT, and ART services. The overall objective of this study is to develop and test a pilot intervention in central Mozambique to implement the new WHO guidelines, and increase the proportion of HIV-positive pregnant women in target ANC clinics who start ART prior to delivery, without reducing ART adherence in the first 3 months of therapy. The intervention will emphasize a WHO defined "Option B+" approach; HIV-positive mothers will be referred for ART at the time they receive a positive HIV test result in their first ANC visit. The project utilizes an innovative formative research process, which has already been completed, and a stepped wedge implementation science design to evaluate the intervention. The entire study is being conducted in close collaboration with the Center for Operations Research in Beira (known by its Portuguese acronym as CIOB) that is one of three research centers in Mozambique managed by the MOH National Institute of Health (the research arm of the MoH).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Sofala
-
Beira, Sofala, Mozambique
- Beira Operations Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Pregnant women who test HIV-positive in antenatal care services at target health facilities
Exclusion Criteria:
- Pregnant women who arrived at health facilities who already have tested positive
- HIV-positive pregnant women who cannot start ART
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Adherence and retention intervention
Implementation of adherence and retention package
|
Based on formative research findings, the following core components of the B+ study intervention have been designed and will be stepped in at the study sites to improve early retention in care and adherence:
|
|
No Intervention: Control
Clusters continue without intervention package
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Retention at 30 days
Time Frame: 45 days
|
The primary outcome measure for Aim 3 is the proportion of HIV-positive pregnant women tested at the participating ANC sites that successfully initiates appropriate ART and returns for their scheduled 30-day visit for pharmacy refill and evaluation within 45 days.
|
45 days
|
|
Adherence at 90 days
Time Frame: 90 days
|
The primary outcome measure for Aim 4 is the ART adherence rate through 90 days after ART initiation.
|
90 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Rachel Chapman, PhD, University of Washington
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 42773
- 1R01HD074557-01 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
Duke UniversityGilead SciencesRecruitingHIV Prevention | HIV Pre-exposure Prophylaxis | HIV Prevention Program | HIV Prevention and Care | HIV Pre-exposure Prophylaxis UseUnited States
-
Federal University of São PauloGilead SciencesCompleted
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
University of Alabama at BirminghamNational Institute of Mental Health (NIMH)RecruitingPrEP | HIV | HIV Prevention | PrEP UptakeUnited States
-
Institute of HIV Research and Innovation Foundation...National Institutes of Health (NIH)RecruitingHIV Prevention | PrEP Adherence | HIV Related StigmaThailand
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH)RecruitingFeasibility | HIV Prevention | PrEP Uptake | Acceptability | HIV Self-testing | Male Partners of HIV-negative Postpartum WomenSouth Africa
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of PennsylvaniaNational Institute of Mental Health (NIMH); University of BotswanaRecruitingPregnancy | HIV | Post-partum | HIV Antiretroviral Therapy (ART) AdherenceBotswana
Clinical Trials on Adherence and retention package
-
Brown UniversityNational Institute of Mental Health (NIMH); University of Mississippi Medical...CompletedHIV Infections | Preventive MedicineUnited States
-
Brown UniversityNational Institute of Mental Health (NIMH); University of Mississippi Medical... and other collaboratorsRecruiting
-
University Hospital, Basel, SwitzerlandCompleted
-
Pardis Specialized Wellness InstituteActive, not recruiting
-
University of North Carolina, Chapel HillCenters for Disease Control and Prevention; Centre for Infectious Disease Research...Completed
-
Elizabeth Glaser Pediatric AIDS FoundationCenters for Disease Control and PreventionCompleted
-
Boston UniversityWorld Bank (Lead institution); Republic of South Africa National Department...CompletedHypertension | Diabetes | HIV | TuberculosisSouth Africa
-
The Hong Kong Polytechnic UniversityCompletedDepression | Type 2 DiabetesHong Kong
-
University of MalayaRecruitingTuberculosis (TB)Malaysia
-
Centre Hospitalier Universitaire de NiceCompletedReproductive DisorderFrance